Translational Cancer Therapeutics Laboratory

The Francis Crick Institute - London, UK
e-mail: charles.swanton[at]crick.ac.uk
webpage: www.crick.ac.uk/research/a-z-researchers/researchers-p-s/charles-swanton

CRUK Lung Cancer Centre of Excellence
UCL Cancer Institute

Senior Group Leader
Division of Molecular Genetics
The Netherlands Cancer Institute - Amsterdam, NL
e-mail: a.berns[at]nki.nl
webpage: www.nki.nl/divisions/molecular-genetics/berns-a-group/

Guest speaker
Session II: Using mouse models as preclinical avatars for the development of precision cancer medicine

Dept. of Medicine, Hematology and Medical Oncology
Sandra and Edward Meyer Cancer Center / Weill Cornell Medicine - New York, US
e-mail: lud2005[at]med.cornell.edu
webpage: http://www.dowlab.org/work/

Guest speaker
Session II: Using mouse models as preclinical avatars for the development of precision cancer medicine

Head of the Thoracic Tumors Group
Oncology Department
Vall d'Hebron University Hospital - Barcelona, ES
e-mail: efelip[at]vhio.net
webpage: www.vhio.net/research-team/en_enriqueta-felip.php

Guest speaker
Session III: Novel approaches for targeted intervention in solid tumors, lymphomas and leukemias

Department of Medical Oncology
Dana-Farber Cancer Institute and Harvard Medical School - Boston, US
e-mail: gordon_freeman[at]dfci.harvard.edu
webpage: www.dfhcc.harvard.edu/insider/member-detail/member/gordon-j-freeman-phd/

Guest speaker
Session IV: Immune checkpoint blockade as a novel therapeutic approach

Wellcome Trust Sanger Institute - Cambridge, UK
e-mail: mathew.garnett[at]sanger.ac.uk
webpage: www.sanger.ac.uk/people/directory/garnett-mathew

Guest speaker
Session I: Discovering basic principles of actionable genomic aberrations in cancer/tumor evolution/acquired resistance

Barts Cancer Institute
Queen Mary University of London - London, UK
e-mail: h.j.toulson[at]qmul.ac.uk
webpage: cll.ucsd.edu/faculty_bios/gribben.html

Guest speaker
Session III: Novel approaches for targeted intervention in solid tumors, lymphomas and leukemias

Unit for RNA Biology
Institute of Clinical Chemistry and Clinical Pharmacology - Univ. of Bonn
Bonn, DE
e-mail: michael.hoelzel[at]ukb.uni-bonn.de
webpage: www.meb.uni-bonn.de/klinpharm/index.php

Guest speaker
Session IV: Immune checkpoint blockade as a novel therapeutic approach

Cancer Research UK Manchester Institute
University of Manchester - Manchester, UK
e-mail: richard.marais[at]cruk.manchester.ac.uk
webpage: www.cruk.manchester.ac.uk/Research/CRUK-MI-Groups/Molecular-Oncology/Home

Guest speaker
Session III: Novel approaches for targeted intervention in solid tumors, lymphomas and leukemias

Dana-Farber Cancer Institute
Harvard Medical School - Boston, US
e-mail: matthew_meyerson[at]dfci.harvard.edu
webpage: meyersonlab.dana-farber.org/matthew-meyerson.html

Guest speaker
Session III: Novel approaches for targeted intervention in solid tumors, lymphomas and leukemias

Department of Clinical Oncology of Sciences
The Chinese University of Hong Kong - Hong Kong, HK
e-mail: tony[at]clo.cuhk.edu.hk
webpage: www.med.cuhk.edu.hk/eng/about_us/faculty_management/DepartmentChairmen/Oncology.jsp

Guest speaker
Session III: Novel approaches for targeted intervention in solid tumors, lymphomas and leukemias

Division of Genetics
Beth Israel Deaconess Medical Center - Boston, US
e-mail: ppandolf[at]bidmc.harvard.edu
webpage: www.bidmc.org/Research/Departments/Medicine/Divisions/Genetics/Pandolfi-Lab.aspx

Guest speaker
Session II: Using mouse models as preclinical avatars for the development of precision cancer medicine

Oncology Translational Medicine
Roche Pharma Research and Early Development - Basel, CH
webpage: http://www.roche.com/research_and_development/who_we_are_how_we_work/our_structure/pred/meet_our_leaders/meet_william_pao.htm

Guest speaker
Session IV: Immune checkpoint blockade as a novel therapeutic approach

German Research Cancer Center - Heidelberg, DE
e-mail: s.pfister[at]dkfz.de
webpage: www.dkfz.de/en/paediatrische-neuroonkologie

Guest speaker
Session I: Discovering basic principles of actionable genomic aberrations in cancer/tumor evolution/acquired resistance

Departments of Pediatrics and Genetics
Stanford University Medical Center - Stanford, US
e-mail: julsage[at]stanford.edu
webpage: med.stanford.edu/profiles/julien-sage

Guest speaker
Session II: Using mouse models as preclinical avatars for the development of precision cancer medicine

II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar
Technische Universität München - Munich, DE
e-mail: dieter.saur[at]tum.de
webpage: www.med2.mri.tum.de/de/team/cv/saur_cv.php

Guest speaker
Session II: Using mouse models as preclinical avatars for the development of precision cancer medicine

Department of Dermatology, Venerology and Allergology
University Hospital Essen - Essen, DE
e-mail: dirk.schadendorf[at]uk-essen.de
webpage: www.uk-essen.de/en/kliniken0/dermatologie0

Guest speaker
Session IV: Immune checkpoint blockade as a novel therapeutic approach

Director of the Molecular Cancer Research Center at the Charité - Berlin, DE
e-mail: clemens.schmitt[at]charite.de
webpage: www.mdc-berlin.de/1153790/de/research/research_teams/cancer_genetics_and_cellular_stress_responses

Guest speaker
Session III: Novel approaches for targeted intervention in solid tumors, lymphomas and leukemias

Broad Institute and Dana-Farber Cancer Institute - Cambridge, US
e-mail: mailto:wsellers[at]broadinstitute.org
webpage: https://www.broadinstitute.org/news/william-sellers-appointed-faculty-broad-institute-dana-farber-cancer-institute-and-harvard

Guest speaker
Session I: Discovering basic principles of actionable genomic aberrations in cancer/tumor evolution/acquired resistance

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, US
e-mail: mailto: Jeffrey.Sosman[at]nm.org
webpage: http://cancer.northwestern.edu/news/sosman2016

Guest speaker
Session I: Discovering basic principles of actionable genomic aberrations in cancer/tumor evolution/acquired resistance

National Cancer Institute
Center for Cancer Research - Bethesda, US
e-mail: lstaudt[at]box-l.nih.gov
webpage: ccr.cancer.gov/Lymphoid-Malignancies-Branch/louis-m-staudt

Guest speaker
Session I: Discovering basic principles of actionable genomic aberrations in cancer/tumor evolution/acquired resistance

Department of Dermatology, University Hospital - Magdeburg, DE
e-mail: thomas.tueting[at]med.ovgu.de
webpage: www.khau.ovgu.de/Team/Klinikleitung.html

Guest speaker
Session IV: Immune checkpoint blockade as a novel therapeutic approach

Department of Microbiology and Institute for Immunology, University of Pennsylvania - Philadelphia, US
e-mail: wherry[at]mail.med.upenn.edu
webpage: www.med.upenn.edu/wherrylab

Guest speaker
Session IV: Immune checkpoint blockade as a novel therapeutic approach

Dana-Farber Cancer Institute, Harvard Medical School - Boston, US
e-mail: kwong1[at]partners.org
webpage: www.dfhcc.harvard.edu/insider/member-detail/member/kwok-kin-wong-md-phd

Guest speaker
Session II: Using mouse models as preclinical avatars for the development of precision cancer medicine